

ECE 2024

26th European Congress of Endocrinology

11–14 May 2024, Stockholm, Sweden



A Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-3813, a Novel, Small Peptide Growth Hormone Receptor Antagonist, in Healthy Subjects

Soraya Allas¹, Thibaud Weiler¹, Guillaume Ravel¹, Colm Farrell², Sophie Fillon¹, Taha Ould Rouis¹,
Michael D. Culler³, Michel Ovize¹, Mark Sumeray³, Aart Jan Van der Lely⁴

¹Amolyt Pharma, Ecully, France, ²ICON PLC, Reading, United Kingdom, ³Amolyt Pharma, Cambridge, MA, USA,

⁴Erasmus University Medical Center, Rotterdam, Netherlands





CONFLICT OF INTEREST

Soraya Allas

I have the following potential conflicts of interest to report:

- Research Contracts
- Consulting
- Employment in the Industry – Amolyt Pharma
- Stockholder of a healthcare company
- Owner of a healthcare company
- Other(s)

I declare that I have no potential conflict of interest.



INTRODUCTION


- Acromegaly

- Rare disease caused by the hypersecretion of GH from a pituitary tumor which in-turn stimulates the over production of IGF-1 from the liver
- Treatment with somastostain analogs (SSA) monotherapy does not provide optimal control of serum IGF-1 levels in most patients

- AZP-3813

- Novel, 16 amino acid peptide GH receptor antagonist
- Long half-life
- Being developped for the treament of acromegaly in patients insufficiently controlled with SSAs

PHASE 1 STUDY DESIGN & SUBJECTS



Sequential cohorts were administered ascending doses of AZP-3813 or placebo by SC injection in the abdominal wall

Study Population



- Healthy Male or Female subjects of nonchildbearing potential
- Age: 18 to 65 years inclusive
- BMI: 19 to 28 kg/m²

Study Endpoints

- Safety and Tolerability
- Pharmacokinetics
- Pharmacodynamics: serum IGF-1 levels


PHARMACOKINETICS

Mean AZP-3813 Plasma Concentrations \pm SEM (ng/mL)




- Cmax and AUC increased in a dose proportional manner.
- Half life ($t_{1/2}$) \sim 20-22h consistent with Once a Day dosing.
- Accumulation ratio equal to 1,75.

MEAN % CHANGE FROM BASELINE IN SERUM IGF-1



- Rapid dose related decrease IGF-1 levels at dose of 10 mg and above
- More prolonged reduction at higher dose (at 120 mg up to 72 hours)




- Gradual decrease in IGF-1
- Greater effect after 14 days compared to single administration, consistent with a cumulative effect following repeated administration
- Maximum % change from baseline adjusted to placebo ~ 50%

CONCLUSION

- Good tolerability with no safety concerns
- The half life ($t_{1/2}$) of AZP-3813 was estimated to be 20-22 hours
- Repeated administration of AZP-3813 induced a gradual and sustained dose-related decrease in IGF-1 levels consistent with a cumulative effect
- Collectively, the data support further testing in patients with acromegaly.

THANK YOU!



Pont Bonaparte, Lyon